Journal
ENDOCRINE-RELATED CANCER
Volume 22, Issue 5, Pages R279-R300Publisher
BIOSCIENTIFICA LTD
DOI: 10.1530/ERC-15-0355
Keywords
antiestrogen; aromatase inhibitor; breast cancer; endocrine-resistance; estrogen receptor; miRNA; tamoxifen
Categories
Funding
- National Institutes of Health [R01 CA138410]
- University of Louisville School of Medicine
Ask authors/readers for more resources
Therapies targeting estrogen receptor alpha (ER alpha), including selective ER modulators such as tamoxifen, selective ER downregulators such as fulvestrant (ICI 182 780), and aromatase inhibitors such as letrozole, are successfully used in treating breast cancer patients whose initial tumor expresses ER alpha. Unfortunately, the effectiveness of endocrine therapies is limited by acquired resistance. The role of microRNAs (miRNAs) in the progression of endocrine-resistant breast cancer is of keen interest in developing biomarkers and therapies to counter metastatic disease. This review focuses on miRNAs implicated as disruptors of antiestrogen therapies, their bona fide gene targets and associated pathways promoting endocrine resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available